Literature DB >> 26884100

Polyarteritis nodosa: A contemporary overview.

Armando De Virgilio1, Antonio Greco2, Giuseppe Magliulo2, Andrea Gallo3, Giovanni Ruoppolo2, Michela Conte4, Salvatore Martellucci3, Marco de Vincentiis2.   

Abstract

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis predominantly targeting medium-sized arteries. PAN is a rare form of vasculitis, and the precise frequency of this disease is difficult to determine. The major environmental factor associated with PAN is HBV infection. The pathogenesis of "idiopathic PAN" remains enigmatic, although the clinical responses to immunosuppressive therapy support the concept that immunological mechanisms play an active pathogenic role. The spectrum of disease ranges from involving a single organ to polyvisceral failure. Any organ might be affected; however, for reasons that are not understood, PAN does not affect the lungs. In addition to the systemic idiopathic form, called "idiopathic generalized PAN," there are 2 clinical variants of this disease: "cutaneous PAN" and "hepatitis B virus (HBV)-associated PAN". Diagnosis requires the integration of clinical, angiographic, and biopsy findings. The overall prognosis of this disease has been improved in recent decades, primarily reflecting early diagnosis and more effective treatments. Idiopathic generalized PAN should be treated with a combination of glucocorticoids and cyclophosphamide. The treatment of HBV-associated PAN involves a different approach, centered on the use of an antiviral agent to control the infection. The therapy for cutaneous PAN requires a less aggressive approach based on the administration of non-steroidal anti-inflammatory drugs over short periods of time.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Cyclophosphamide; Hepatitis B; Immunology; Polyarteritis nodosa; Vasculitis

Mesh:

Substances:

Year:  2016        PMID: 26884100     DOI: 10.1016/j.autrev.2016.02.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  42 in total

Review 1.  Gastrointestinal aspects of vasculitides.

Authors:  Medha Soowamber; Adam V Weizman; Christian Pagnoux
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-23       Impact factor: 46.802

2.  Abdominal pain leading to incidental finding of polyarteritis nodosa.

Authors:  Ella Starobinska; Kawanjit Sekhon; Jawad Bilal
Journal:  BMJ Case Rep       Date:  2018-06-28

Review 3.  Childhood- Versus Adult-Onset Primary Vasculitides: Are They Part of the Same Clinical Spectrum?

Authors:  Renato Ferrandiz-Espadin; Manuel Ferrandiz-Zavaler
Journal:  Curr Rheumatol Rep       Date:  2019-08-29       Impact factor: 4.592

4.  Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa.

Authors:  Yoon-Jeong Oh; Sung Soo Ahn; Eun Seong Park; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2017-03-24       Impact factor: 2.631

Review 5.  Infliximab for the treatment of refractory polyarteritis nodosa.

Authors:  Shira Ginsberg; Itzhak Rosner; Gleb Slobodin; Michael Rozenbaum; Lisa Kaly; Nizar Jiries; Nina Boulman; Abid Awisat; Haya Hussein; Irina Novofastovski; Amal Silawy; Doron Rimar
Journal:  Clin Rheumatol       Date:  2019-04-10       Impact factor: 2.980

6.  Chronic hepatitis B viral infection among RA patients-a cross-sectional control study.

Authors:  Naim Mahroum; Abdulla Watad; Shmuel Tiosano; Ashraf Hejly; Hussein Mahagna; Roy Waknin; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

Review 7.  Vasculitic and autoimmune wounds.

Authors:  Victoria K Shanmugam; Divya Angra; Hamza Rahimi; Sean McNish
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2016-12-14

Review 8.  Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature.

Authors:  Martin Krusche; Nikolas Ruffer; Ina Kötter
Journal:  Rheumatol Int       Date:  2018-11-21       Impact factor: 2.631

Review 9.  [Muscular polyarteritis nodosa-a case-based review].

Authors:  M Krusche; N Ruffer; T Kubacki; J Matschke; I Kötter
Journal:  Z Rheumatol       Date:  2019-03       Impact factor: 1.372

10.  HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study.

Authors:  Sang-Won Lee; Do Young Kim; Sang Hoon Ahn; Yong-Beom Park; Kwang-Hyub Han; Jun Yong Park
Journal:  Rheumatol Int       Date:  2018-05-12       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.